BRPI0513777A - composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo - Google Patents

composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo

Info

Publication number
BRPI0513777A
BRPI0513777A BRPI0513777-2A BRPI0513777A BRPI0513777A BR PI0513777 A BRPI0513777 A BR PI0513777A BR PI0513777 A BRPI0513777 A BR PI0513777A BR PI0513777 A BRPI0513777 A BR PI0513777A
Authority
BR
Brazil
Prior art keywords
nitrogen
formula
salt
compound
ring
Prior art date
Application number
BRPI0513777-2A
Other languages
English (en)
Inventor
Lisa Selsam Beavers
Serge Louis Boulet
Terry Patrick Finn
Robert Alan Gadski
William Joseph Hornback
Cynthia Darshini Jesudason
Richard Todd Pickard
Freddie Craig Stevens
Grant Mattews Vaught
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0513777A publication Critical patent/BRPI0513777A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

COMPOSTO OU UM SAL DO MESMO, COMPOSIçãO FARMACêUTICA, E, USO DE UM COMPOSTO OU DE UM SAL DO MESMO A presente invenção revela compostos inéditos de aril oxazol de Fórmula I (I), ou seus sais farmaceuticamente aceitáveis, que apresentam atividade antagonista ou agonista inversa de receptor de histamina-H3, e também métodos para preparar e usar referidos compostos. Em outra concretização, a invenção revela composições farmacêuticas compreendendo compostos de Fórmula I, e também métodos de usar estas composições para tratar obesidade, deficiências cognitivas, narcolepsia e outras doenças relacionadas com receptor de histamina H3. Fórmula I (I) ou um sal farmaceuticamente aceitável da mesma, em que: m é, independentemente, em cada ocorrência, 1, 2 ou 3, Z representa independentemente carbono (substituído com hidrogênio ou pelos substituintes opcionais aqui indicados) ou nitrogênio, desde que, quando Z for nitrogênio, então R6 não seja ligado a Z; R1 e R2 são independentemente -(Cl-C7) alquila (opcionalmente substituído com de um a três halogênios), ou R1 e R2 e o nitrogênio a que estão ligados formam um anel azetidinila, um anel pirrolidinila, ou um anel piperidinila, sendo que, adicionalmente, um anel pirrolidinila ou anel piperidinila, sendo que, adicionalmente, o anel azetidinila, pirrolidinila, ou piperidinila assim formado pode ser opcionalmente substituído de uma a três vezes com R5; R6 é, independentemente, em cada ocorrência, -H, -halogênio, ou -CH~ 3~.
BRPI0513777-2A 2004-07-26 2005-07-14 composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo BRPI0513777A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59119104P 2004-07-26 2004-07-26
PCT/US2005/024883 WO2006019833A1 (en) 2004-07-26 2005-07-14 Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
BRPI0513777A true BRPI0513777A (pt) 2008-05-13

Family

ID=35134220

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513777-2A BRPI0513777A (pt) 2004-07-26 2005-07-14 composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo

Country Status (17)

Country Link
US (1) US7666871B2 (pt)
EP (1) EP1786790B1 (pt)
JP (1) JP4982367B2 (pt)
CN (1) CN1989115B (pt)
AT (1) ATE432926T1 (pt)
AU (1) AU2005275183B2 (pt)
BR (1) BRPI0513777A (pt)
CA (1) CA2575081C (pt)
CY (1) CY1109493T1 (pt)
DE (1) DE602005014786D1 (pt)
DK (1) DK1786790T3 (pt)
ES (1) ES2325865T3 (pt)
MX (1) MX2007001029A (pt)
PL (1) PL1786790T3 (pt)
PT (1) PT1786790E (pt)
SI (1) SI1786790T1 (pt)
WO (1) WO2006019833A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008301B2 (en) * 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
WO2006089076A2 (en) 2005-02-18 2006-08-24 Neurogen Corporation Thiazole amides, imidazole amides and related analogues
US7790720B2 (en) 2005-03-31 2010-09-07 Ucb Pharma, S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
KR101439557B1 (ko) 2005-11-15 2014-09-11 오츠카 세이야쿠 가부시키가이샤 옥사졸 화합물 및 제약 조성물
MX2008011791A (es) 2006-03-15 2008-09-25 Wyeth Corp Azaciclilaminas-n-sustituidas como antagonistas de histamina-3.
EP2024327A1 (de) * 2006-05-19 2009-02-18 Basf Se Benzoylsubstituierte alanine
CN101432261A (zh) 2006-05-19 2009-05-13 惠氏公司 作为组织胺-3拮抗剂的n-苯甲酰基-吡咯烷-3-基胺和n-苄基-吡咯烷-3-基胺
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
CA2693138A1 (en) * 2007-07-16 2009-01-22 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
WO2009126782A1 (en) * 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
US8383829B2 (en) * 2008-04-15 2013-02-26 Konica Minolta Holdings, Inc. Electrochromic compound, electrode, and display element
SA110310332B1 (ar) * 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
MX2012015102A (es) 2010-07-06 2013-05-01 Astrazeneca Ab Agentes terapeuticos 976.
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
JP6307096B2 (ja) 2013-01-23 2018-04-04 アストラゼネカ アクチボラグ 化合物
JP6807841B2 (ja) 2014-12-18 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーター及びその使用
CA2988147C (en) 2015-06-03 2023-06-13 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
RS62959B1 (sr) 2017-01-11 2022-03-31 Alkermes Inc Biciklični inhibitori histon-deacetilaze
PT3664802T (pt) 2017-08-07 2022-05-24 Alkermes Inc Inibidores bicíclicos de histona-desacetilase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819037A1 (de) * 1988-06-04 1989-12-14 Hoechst Ag 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden
AU674613B2 (en) * 1993-09-28 1997-01-02 Otsuka Pharmaceutical Co., Ltd. Quinoxaline derivative as antidiabetic agent
AU3957600A (en) * 1999-04-26 2000-11-10 Boehringer Ingelheim International Gmbh Piperidyl-imidazole derivatives, their preparations and therapeutic uses
CA2441080A1 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
JP4597524B2 (ja) 2002-02-01 2010-12-15 ハイ・ポイント・ファーマスーティカルズ、エルエルシー アミノアルキル置換されたアゼチジン、ピロリジン、ピペリジン、およびアゼパンのアミド
DE10259244A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
US7259262B2 (en) * 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents

Also Published As

Publication number Publication date
US20070197604A1 (en) 2007-08-23
CY1109493T1 (el) 2014-08-13
CA2575081A1 (en) 2006-02-23
PT1786790E (pt) 2009-08-18
EP1786790A1 (en) 2007-05-23
JP2008507579A (ja) 2008-03-13
AU2005275183A1 (en) 2006-02-23
DE602005014786D1 (de) 2009-07-16
ES2325865T3 (es) 2009-09-22
WO2006019833A1 (en) 2006-02-23
CN1989115A (zh) 2007-06-27
SI1786790T1 (sl) 2009-10-31
AU2005275183B2 (en) 2011-03-17
ATE432926T1 (de) 2009-06-15
EP1786790B1 (en) 2009-06-03
US7666871B2 (en) 2010-02-23
PL1786790T3 (pl) 2009-10-30
DK1786790T3 (da) 2009-07-20
CA2575081C (en) 2013-05-07
CN1989115B (zh) 2012-03-21
JP4982367B2 (ja) 2012-07-25
MX2007001029A (es) 2007-04-12

Similar Documents

Publication Publication Date Title
BRPI0513777A (pt) composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo
RS51137B (sr) Derivat benzimidazola i njegova upotreba kao antagonista receptora aii
NZ588121A (en) Novel estrogen receptor ligands
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
AR035548A1 (es) Compuestos organicos
TW200716528A (en) Cyclopropanecarboxamide derivatives
MX2007005709A (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos.
EA200970705A1 (ru) Новые фармацевтические композиции
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
ATE325796T1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
GB0701366D0 (en) Novel pharmaceutical compositions
AR046085A1 (es) Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico
DE602005007064D1 (de) Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
MY149973A (en) 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
ATE523488T1 (de) Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung
BRPI0415109A (pt) compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
TW200612924A (en) Oxazolidinones containing oxindoles as antibacterial agents
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
EA201071259A1 (ru) Спиро(пиперидин-4,2-пирролидин)-1-(3,5-трифторметилфенил)метилкарбоксамиды в качестве антагонистов рецептора nk1 тахикинина
TH99116B (th) สารประกอบไอโซอินโดล-อิมีด และสารผสมซึ่งประกอบรวมด้วยสารประกอบไอโซอินโดล-อิมีด และวิธีการใช้สารประกอบไอโซอินโดล-อิมีด
TW200602046A (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.